Qualitative Study About Psychedelics Using in Psychiatric Disorders (PSYCHEQUALI)

This observational, case-only study (n=25) will investigate the self-administered therapeutic use of psychedelics in people with psychiatric disorders.

Led by University Hospital, Toulouse, the study aims to understand the current use of psychedelics in France among individuals who have used these substances to suppress or alleviate psychiatric symptoms within diagnosed pathologies. The study will involve semi-structured interviews to collect data, which will then undergo thematic analysis.

Participants eligible for the study include adults diagnosed with a psychiatric disorder who have used psychedelic or related substances for therapeutic purposes. Exclusion criteria include individuals who do not speak or understand French and those under protection, guardianship, or curatorship.

The estimated start date for the study was November 30, 2023, with an estimated completion date of March 10, 2025, and an anticipated enrolment of 25 participants.

Country France
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University Hospital Toulouse
The University Hospital of Toulouse (CHU de Toulouse) is a leading medical institution located in Toulouse, France. It provides comprehensive healthcare services, conducts medical research, and offers educational programs for healthcare professionals

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.